We examined 52 asymptomatic patients with IgM monoclonal gammopathy and correlated anti-myelin-associated glycoprotein (anti-MAG) IgM with the presence of subclinical neuropathy and, in 24 of these patients, with the development of symptomatic neuropathy during a follow-up interval of 40 to 144 months (mean, 75.3 months). Three of 6 patients (50%) with high (>1/6,400) anti-MAG IgM had subclinical neuropathy at entry compared with 2 of 46 patients (4.3%) with low or no reactivity. At follow-up, a symptomatic neuropathy occurred in 3 of 4 patients with high reactivity and in 3 of 21 patients with low or no reactivity. The correlation of high anti-MAG IgM with the presence of subclinical neuropathy or the development of symptomatic neuropathy supports its pathogenetic role in the neuropathy.

Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy / N. Meucci, L. Baldini, A. Cappellari, A. Di Troia, S. Allaria, G. Scarlato, E. Nobile-Orazio. - In: ANNALS OF NEUROLOGY. - ISSN 0364-5134. - 46:1(1999 Jul), pp. 119-22-122. [10.1002/1531-8249(199907)46:1<119::AID-ANA18>3.0.CO;2-H]

Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy

L. Baldini;G. Scarlato;E. Nobile-Orazio
1999-07

Abstract

We examined 52 asymptomatic patients with IgM monoclonal gammopathy and correlated anti-myelin-associated glycoprotein (anti-MAG) IgM with the presence of subclinical neuropathy and, in 24 of these patients, with the development of symptomatic neuropathy during a follow-up interval of 40 to 144 months (mean, 75.3 months). Three of 6 patients (50%) with high (>1/6,400) anti-MAG IgM had subclinical neuropathy at entry compared with 2 of 46 patients (4.3%) with low or no reactivity. At follow-up, a symptomatic neuropathy occurred in 3 of 4 patients with high reactivity and in 3 of 21 patients with low or no reactivity. The correlation of high anti-MAG IgM with the presence of subclinical neuropathy or the development of symptomatic neuropathy supports its pathogenetic role in the neuropathy.
Myelin-Associated Glycoprotein; Humans; Nervous System Diseases; Adult; Aged; Paraproteinemias; Middle Aged; Follow-Up Studies; Male; Female; Immunoglobulin M
Settore MED/26 - Neurologia
Settore MED/15 - Malattie del Sangue
ANNALS OF NEUROLOGY
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/185647
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 32
social impact